Oral drug delivery system
Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
1. A composition comprising:
a drug;
sucrose acetate isobutyrate (SAIB);
about 1 weight percent to about 8.6 weight percent of a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons; and
a solvent.
2. The composition of claim 1 , wherein the drug is present in an amount ranging from about 2 mg to about 250 mg.
3. The composition of claim 1 , wherein the drug comprises an opioid, a central nervous system (CNS) depressant, or a stimulant.
4. The composition of claim 1 , wherein the drug comprises hydrocodone, hydromorphone, levorphanol, morphine, oxymorphone, or oxycodone.
5. The composition of claim 1 , wherein the drug comprises a stimulant selected from dextroamphetamine and methylphenidate.
6. The composition of claim 1 , wherein the drug comprises methylphenidate.
7. The composition of claim 1 , wherein the composition comprises from about 20 weight percent to about 90 weight percent of the SAIB.
8. The composition of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38%.
9. The composition of claim 1 , wherein the CAB has an acetyl content ranging from about 13% to about 30%.
10. The composition of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38% and an acetyl content ranging from about 13% to about 30%.
11. The composition of claim 1 , wherein the CAB has at least one feature selected from a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%.
12. The composition of claim 1 , wherein the composition comprises from about 20 weight percent to about 50 weight percent of the solvent.
13. The composition of claim 1 , wherein the solvent comprises propylene carbonate, N-methylpyrrolidone (NMP), glycofurol, alpha-tocopherol, diethyl phthalate, or polyethylene glycol 400 (PEG 400).
14. The composition of claim 1 , wherein the solvent comprises triacetin or ethyl lactate.
15. The composition of claim 1 , wherein the solvent comprises triacetin.
16. The composition of claim 1 , further comprising a member selected from caprylic/capric triglyceride, isopropyl myristate (IPM), ethyl oleate, dimethyl phthalate, and benzyl benzoate.
17. The composition of claim 1 , further comprising isopropyl myristate (IPM).
18. The composition of claim 17 , wherein the composition comprises from about 1 weight percent to about 75 weight percent of the IPM.
19. The composition of claim 17 , wherein the composition comprises:
from about 20 weight percent to about 90 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB;
from about 1 weight percent to about 75 weight percent of the IPM; and
from about 20 weight percent to about 50 weight percent of the solvent.
20. The composition of claim 19 , wherein the composition comprises from 3 weight percent to 7.8 weight percent of the CAB.
21. The composition of claim 19 , wherein the composition comprises from 0.1 weight percent to 10 weight percent of the IPM.
22. The composition of claim 19 , wherein the composition comprises:
from about 30 weight percent to about 70 weight percent of the SAIB;
from about 1 weight percent to about 8.6 weight percent of the CAB;
from about 1 weight percent to about 75 weight percent of the IPM; and
from about 25 weight percent to about 48 weight percent of the solvent.
23. The composition of claim 1 , wherein the composition is contained in a capsule.
24. The composition of claim 23 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.
25. The composition of claim 23 , wherein the capsule comprises a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.